Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
AIM ImmunoTech Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
AIM
American
2834
https://aimimmuno.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for AIM ImmunoTech Inc
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
- Apr 18th, 2024 12:45 pm
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
- Apr 15th, 2024 12:55 pm
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
- Apr 10th, 2024 12:21 pm
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Apr 2nd, 2024 11:30 am
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
- Mar 28th, 2024 12:05 pm
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
- Mar 26th, 2024 1:05 pm
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
- Mar 25th, 2024 1:05 pm
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity
- Mar 15th, 2024 12:45 pm
AIM ImmunoTech Announces Launch of CEO Corner Platform
- Mar 7th, 2024 1:45 pm
AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
- Feb 29th, 2024 1:45 pm
AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
- Feb 14th, 2024 1:55 pm
AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
- Feb 8th, 2024 1:50 pm
AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
- Jan 24th, 2024 2:10 pm
AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer
- Jan 22nd, 2024 1:55 pm
AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
- Jan 10th, 2024 1:45 pm
AIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting
- Jan 5th, 2024 6:32 pm
Kellner Seeking Expedited Appeal of Delaware Court Finding that Nomination Notice was Properly Denied
- Jan 3rd, 2024 9:05 pm
Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Board’s Determination that Activist Group’s Nominations Are Invalid
- Dec 29th, 2023 1:00 pm
AIM ImmunoTech Provides Update Regarding Annual Meeting
- Nov 28th, 2023 9:30 pm
AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
- Nov 28th, 2023 2:00 am
Scroll